BMS-817399

• UNSPSC Description:

  BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC50), respectively. BMS-817399 can be used for the research of rheumatoid arthritis[1].

• Target Antigen:

  CCR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ccr1-antagonist-2.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@@](CCN1C([C@@H](C(C)C)NC(NCC(C)(O)C)=O)=O)(C(C=C2)=CC=C2Cl)C(C)(C1)C

• Molecular Weight:

  454.00

• References & Citations:

  [1]Santella JB 3rd, et al. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014;57(18):7550-7564.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Phase 2

• CAS Number:

  1202400-18-7